Avadel Pharmaceuticals (AWK) Price & Analysis

Compare

0 Followers

AWK Stock Chart & Stats

Day’s Range― - ―

52-Week Range€5.85 - €15.60

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

$1.27B

Enterprise Value€833.42M

Total Cash (Recent Filing)$81.55M

Total Debt (Recent Filing)$2.73M

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Nov 05, 2025

EPS Estimate

0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.09

Shares Outstanding97,097,640

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue3.77

Enterprise Value/Gross Profit4.21

Enterprise Value/Ebitda125.48

Forecast

1Y Price Target

$17.44

Price Target Upside36.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Market AcceptanceThe once-nightly oxybate (Lumryz) has been well received in the market, and it is expected to continue to expand the oxybate market and take additional market share.

Revenue GrowthAvadel Pharmaceuticals posted strong 2Q25 results with sales of $68.1 million, exceeding prior expectations and leading to an increased FY25 guidance.

Royalty RateThe 3.85% royalty rate on Lumryz sales is seen as a win for Avadel Pharmaceuticals, as it removes litigation overhang and is lower than what investors likely expected.

Strategic LicensingThe strategic licensing agreement with XWPharma to develop and commercialize Valiloxybate is seen as a positive move to broaden Avadel Pharmaceuticals' sleep portfolio.

Bears Say

Litigation ImpactThe update on the litigation outcome slightly derisks Lumryz's potential, contributing to an increased price target for Avadel Pharmaceuticals.

Market CompetitionThe launch of a product that is both once nightly and low sodium could nullify Jazz's advantage and become the go-to oxybate product of choice.

Avadel Pharmaceuticals News

Avadel says court requires 3.85% of Lumryz sales go to Jazz

As previously disclosed, on May 12, 2021, Jazz Pharmaceuticals (JAZZ) filed a formal complaint initiating a lawsuit in...

13d ago

AVDL

JAZZ

Avadel Pharmaceuticals to present new data on LUMRYZ

Avadel Pharmaceuticals (AVDL) announced that new data supporting the use of LUMRYZ as a narcolepsy treatment will be...

25d ago

AVDL

Avadel Pharmaceuticals price target raised to $36 from $24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $36 from $24 and keeps a...

25d ago

AVDL

Avadel Pharmaceuticals price target lowered to $36 from $246 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $36 from $246 and keeps a...

25d ago

AVDL

Avadel Pharmaceuticals assumed with an Outperform at LifeSci Capital

LifeSci Capital analyst Francois Brisebois assumed coverage of Avadel Pharmaceuticals (AVDL) with an Outperform rating and $21 price...

27d ago

AVDL

Avadel Pharmaceuticals initiated with an Equal Weight at Wells Fargo

Wells Fargo analyst Benjamin Burnett initiated coverage of Avadel Pharmaceuticals (AVDL) with an Equal Weight rating and $16...

28d ago

AVDL

Positive Outlook for Avadel Pharmaceuticals Amid Legal Resolution and Strategic Growth Initiatives

Analyst Francois Brisebois of LifeSci Capital maintained a Buy rating on Avadel Pharmaceuticals, boosting the price target to...

13d ago

AVDL

Avadel Pharmaceuticals: Positioned for Growth with Lumryz and Strategic Acquisitions

Leerink Partners analyst Marc Goodman has maintained their bullish stance on AVDL stock, giving a Buy rating on...

22d ago

AVDL

Avadel Pharmaceuticals Signs Global License Agreement for Sleep Drug

The latest announcement is out from Avadel Pharmaceuticals ( ($AVDL) ). On August 29, 2025, Avadel Pharmaceuticals entered...

27d ago

AVDL

Avadel Pharmaceuticals: Strong Sales Growth and Strategic Positioning Drive Buy Rating

LifeSci Capital analyst maintained a Buy rating on Avadel Pharmaceuticals today and set a price target of $21.00....

27d ago

AVDL

Avadel Pharmaceuticals price target raised to $20 from $13 at UBS

UBS analyst Ashwani Verma raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $20 from $13 and...

1M ago

AVDL

Avadel Pharmaceuticals Reports Strong Earnings and Growth

Avadel Pharmaceuticals (($AVDL)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

AVDL

Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $18 from $16 and keeps a...

2M ago

AVDL

Avadel Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $24 from $22 and keeps a...

2M ago

AVDL

AWK FAQ

What was Avadel Pharmaceuticals’s price range in the past 12 months?

Avadel Pharmaceuticals lowest stock price was €5.85 and its highest was €15.60 in the past 12 months.

What is Avadel Pharmaceuticals’s market cap?

Avadel Pharmaceuticals’s market cap is $1.27B.

When is Avadel Pharmaceuticals’s upcoming earnings report date?

Avadel Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 36 days.

How were Avadel Pharmaceuticals’s earnings last quarter?

Avadel Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported €0.085 earnings per share for the quarter, beating the consensus estimate of €0.026 by €0.059.

Is Avadel Pharmaceuticals overvalued?

According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Avadel Pharmaceuticals pay dividends?

Avadel Pharmaceuticals does not currently pay dividends.

What is Avadel Pharmaceuticals’s EPS estimate?

Avadel Pharmaceuticals’s EPS estimate is 0.06.

How many shares outstanding does Avadel Pharmaceuticals have?

Avadel Pharmaceuticals has 97,097,640 shares outstanding.

What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?

Avadel Pharmaceuticals reported an EPS of €0.085 in its last earnings report, beating expectations of €0.026. Following the earnings report the stock price went up 25.532%.

Which hedge fund is a major shareholder of Avadel Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:AWK

Avadel Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-3.63%

Trailing 12-Months

Asset Growth

18.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals (AWK) Earnings & Revenues

Historic Earnings Reports

AWK Company Deck

AWK Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive sentiment with significant growth in patient demand, strong financial performance, and successful litigation outcomes. Although there are some concerns regarding pending royalty determinations and increased operating expenses, the positive aspects significantly outweigh the lowlights, indicating a strong position for future growth.View all DE:AWK earnings summaries

AWK Stock 12 Month Forecast

Average Price Target

€17.44

▲(36.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","31":"€31","12.25":"€12.25","18.5":"€18.5","24.75":"€24.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.70873188,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.4357355452,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.64832528,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.65</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,12.25,18.5,24.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,13.900671683076922,15.301343366153846,16.70201504923077,18.102686732307692,19.503358415384614,20.90403009846154,22.304701781538462,23.705373464615384,25.106045147692306,26.50671683076923,27.907388513846154,29.308060196923076,{"y":30.70873188,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,12.879671965015385,13.25934393003077,13.639015895046153,14.018687860061538,14.398359825076923,14.778031790092308,15.157703755107693,15.537375720123077,15.917047685138462,16.296719650153847,16.67639161516923,17.056063580184617,{"y":17.4357355452,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,12.588332713846153,12.676665427692308,12.764998141538461,12.853330855384616,12.94166356923077,13.029996283076922,13.118328996923077,13.20666171076923,13.294994424615384,13.383327138461539,13.471659852307692,13.559992566153847,{"y":13.64832528,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >